inclusion criteria: * participant is willing and able to give written informed consent for participation in the study. * male or female, aged 18 years or above and in good health as determined by study clinician. participants may have well controlled or mild-moderate comorbidity. * female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. * in the investigator's opinion, participant is able and willing to comply with all trial requirements. * at least 16 weeks after first booster dose of vaccination.

inclusion criteria: * participant is willing and able to give written informed consent for participation in the study. * male or female, aged 18 years or above and in good health as determined by study clinician. participants may have well controlled or mild-moderate comorbidity. * female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. * in the investigator's opinion, participant is able and willing to comply with all trial requirements. * at least 16 weeks after first booster dose of vaccination.

inclusion criteria: participant is willing and able to give written informed consent for participation in the study. male or female, aged 18 years or above and in good health as determined by study clinician. participants may have well controlled or mild-moderate comorbidity. female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. in the investigator's opinion, participant is able and willing to comply with all trial requirements. at least 16 weeks after first booster dose of vaccination.

inclusion criteria: participant is willing and able to give written informed consent for participation in the study. male or female, aged 18 years or above and in good health as determined by study clinician. participants may have well controlled or mild-moderate comorbidity. female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. in the investigator's opinion, participant is able and willing to comply with all trial requirements. at least 16 weeks after first booster dose of vaccination.

inclusion criteria: participant is willing and able to give written informed consent for participation in the study. male or female, aged 18 years or above and in good health as determined by study clinician. participants may have well controlled or mild-moderate comorbidity. female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. in the investigator's opinion, participant is able and willing to comply with all trial requirements. at least 16 weeks after first booster dose of vaccination. sub-optimal response to first booster vaccination, defined sars-cov-2 anti-spike igg< 250 u/ml and/or anti-receptor binding domain (rbd) igg< 100 u/ml [22,23,24] at entry into study. in addition, for inclusion as immuno-compromised people, these are subjects who have one or more of the following medical conditions [25]: active or recent treatment for solid tumor and hematologic malignancies receipt of solid-organ or recent hematopoietic stem cell transplant severe primary immunodeficiency advanced or untreated hiv infection treatment with immunosuppressive medications such as cancer chemotherapeutic agents, tnf blockers, certain biologic agents (e.g., rituximab), and high-dose corticosteroids chronic conditions associated with varying degrees of immune deficit, such as asplenia, chronic kidney and liver disease if the subject is no more than 50 years old, at same time, he or she meets inclusion criteria no. 1 to no.7 this subject is eligible if the subject is more than 50 years old, he or she only meets inclusion criteria no. 1 to no.6, this subject is also eligible

inclusion criteria: participant is willing and able to give written informed consent for participation in the study. male or female, aged 18 years or above and in good health as determined by study clinician. participants may have well controlled or mild-moderate comorbidity. female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. in the investigator's opinion, participant is able and willing to comply with all trial requirements. at least 16 weeks after first booster dose of vaccination. sub-optimal response to first booster vaccination, defined sars-cov-2 anti-spike igg< 250 u/ml and/or anti-receptor binding domain (rbd) igg< 100 u/ml [22,23,24] at entry into study. in addition, for inclusion as immuno-compromised people, these are subjects who have one or more of the following medical conditions [25]: active or recent treatment for solid tumor and hematologic malignancies receipt of solid-organ or recent hematopoietic stem cell transplant severe primary immunodeficiency advanced or untreated hiv infection treatment with immunosuppressive medications such as cancer chemotherapeutic agents, tnf blockers, certain biologic agents (e.g., rituximab), and high-dose corticosteroids chronic conditions associated with varying degrees of immune deficit, such as asplenia, chronic kidney and liver disease if the subject is no more than 50 years old, at same time, he or she meets inclusion criteria no. 1 to no.7 this subject is eligible if the subject is more than 50 years old, he or she only meets inclusion criteria no. 1 to no.6, this subject is also eligible